Biomaterial Database

The prophylactic use of Thio-TEPA, an adjuvant in the treatment of bladder tumours. 1977

W Dobrzecki, and A Kaczmarek

In order to reduce the recurrence rate of bladder tumours, 78 patients with bladder tumours have been treated since November 1973 with topical Thio-TEPA bladder instillations. This method was used as an adjuvant to other forms of therapy. At the time of this review 20 of the patients have been followed up for at least one year following the onset of Thio-TEPA treatment. The total number of recurrences in these patients seems to be reduced. Advantages of topical therapy and indications for treatment are discussed.

UI	MeSH Term	Description	Entries
D012008	Recurrence	The return of a sign, symptom, or disease after a remission.	Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001749	Urinary Bladder Neoplasms	Tumors or cancer of the URINARY BLADDER.	Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013852	Thiotepa	A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	Thio-Tepa,Thiophosphamide,Triethylenethiophosphoramide,AI3-24916,Girostan,NSC-6396,Tespa,Tespamin,Tris(1-aziridinyl)phosphine Sulfide,AI3 24916,AI324916,NSC 6396,NSC6396,Thio Tepa